News

Why 90% of AI Presentations Fail to Impress and What You Can Do About It
Learn how to avoid common AI presentation mistakes and create decks that inspire action with our practical 3-step guide.
Morningstar23d
2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer ... - Morningstar
2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors.
Business Wire25d
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in ... - Business Wire
The Phase 3 VERIFY study (NCT05210790) is an ongoing, three-part, global, randomized, placebo-controlled study evaluating rusfertide in 293 patients with polycythemia vera over a 156-week period.
Yahoo Finance25d
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in ... - Yahoo Finance
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., June 01, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the ...
Indiatimes25d
Meerut drum case: Ex-merchant navy officer's wife Muskan Rastogi plans to study law in jail | Meerut News - Times of India
Muskan Rastogi, accused of murdering her husband, an ex-merchant navy officer, has expressed her desire to study law while incarcerated in Meerut's Chaudhary Charan Singh District Jail. Claiming ...
Morningstar28d
Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - Morningstar
Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting PR Newswire SHELTON, Conn., May ...